Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands

Jy, Kim; S, Lee; Cho, KJ; Sy, Kim; Sy, Nam; Sh, Choi; Jl, Roh; Ek, Choi; Kim, Jae‐Hun; Sy, Song; Hs, Shin; Sk, Chang; Sd, Ahn

doi:10.1259/bjr/21574486

Cited by 43 publications

(71 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, SDC metastases occur earlier and develop more rapidly, suggesting that the efficacy of lung metastasectomy for SDC may be insufficient when compared to its efficacy for ACC. In the case presented herein, SDC developed in the submandibular gland and the patient had lymph node metastases at initial diagnosis, as described previously (2,(7)(8)(9)(10)(11)(12). Radical tumor resection with ipsilateral neck dissection were first performed, followed by lung metastasectomy via VATS for left lower lung metastasis and adjuvant chemotherapy.…”

Section: Sdc Was First Described In 1968 Bymentioning

confidence: 67%

“…Kleinsasser et al (25). This type of cancer is considered to be among the most aggressive salivary gland carcinomas due to the high frequency of local recurrence, as well as associated cervical lymph node and distant metastases (2,(7)(8)(9)(10)(11)(12). The most common treatment for SDC is surgery, particularly extended radical resection and ipsilateral neck dissection, with postoperative radiotherapy (2,6,7).…”

Section: Case Reportmentioning

confidence: 99%

“…Between 2005 and 2015, SDC patients were frequently diagnosed at an advanced stage, as in 55-82% of the cases the disease had already spread to the cervical lymph nodes on first diagnosis. Furthermore, local and regional recurrence and distant metastasis following surgery and postoperative radiotherapy were observed in 11-48, 8-26 and 24-63% of the patients, respectively, with a 5-year survival rate of 42-55% (2,(7)(8)(9)(10)(11)(12).…”

Section: Case Reportmentioning

confidence: 99%

“…The pathological examination revealed that all resection margins were tumor-free, and distant metastasis was not detected at the time. Previous reports led us to consider postoperative adjuvant therapy to prevent local and regional recurrence and distant metastasis (2,(7)(8)(9)(10)(11)(12). Therefore, a systemic molecularly targeted therapy selected for the distant metastasis, along with close follow-up to monitor local and regional recurrence.…”

Section: Sdc Was First Described In 1968 Bymentioning

confidence: 99%

“…The overall 5-year survival rate associated with SDC is low (42-55%) (2,(7)(8)(9)(10)(11)(12). Recent studies have tested molecularly targeted therapies as novel treatment strategies for SDC.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Kawahara

Hiraki

Yoshida

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes. Radical resection of the tumor and submandibular gland with neck dissection were performed. One month after radical surgery, computed tomography (CT) scans indicated metastasis in the lower lobe of the left lung. CT-guided transthoracic fine-needle aspiration biopsy revealed a single metastasis and lung metastasectomy was immediately performed. The tumor cells of the primary lesion and those of the lung metastasis were immunohistochemically positive for epidermal growth factor receptor. One month later, multiple right lung metastases appeared, and the patient was treated with cisplatin/5-fluorouracil (5-FU) chemotherapy plus cetuximab, achieving a complete radiographic response. However, multiple lung metastases developed during adjuvant weekly cetuximab monotherapy. Subsequently, treatment with S-1 and weekly cetuximab was initiated, and the multiple lung metastases have been maintained as stable disease for 5 months. To the best of our knowledge, this is the first report of cetuximab use for the treatment of salivary duct carcinoma. Although cisplatin/5-FU chemotherapy plus cetuximab was efficacious in treating the lung metastasis, cetuximab monotherapy was insufficient for controlling tumor growth.

show abstract

Section: Sdc Was First Described In 1968 Bymentioning

confidence: 67%

Section: Case Reportmentioning

confidence: 99%

Section: Case Reportmentioning

confidence: 99%

Section: Sdc Was First Described In 1968 Bymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Kawahara

Hiraki

Yoshida

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

A nomogram involving immune‐inflammation index for predicting distant metastasis‐free survival of major salivary gland carcinoma following postoperative radiotherapy

Yan

Shen

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Postoperative radiotherapy (PORT) is beneficial in the improvement of local‐regional control and overall survival (OS) for major salivary gland carcinomas (SGCs), and distant metastasis remained the main failure pattern. This study was designed to develop a nomogram model involving immune‐inflammation index to predict distant metastasis‐free survival (DMFS) of major SGCs. Patients and Methods A total of 418 patients with major SGCs following PORT were randomly divided into a training ( n = 334) and validation set ( n = 84). The pre‐radiotherapy neutrophil‐to‐lymphocyte ratio (NLR), and platelet‐to‐lymphocyte ratio (PLR) were calculated and transformed as continuous variables for every patient. Associations between DMFS and variables were performed by univariate and multivariable analysis using Log‐rank and Cox regression methods. A nomogram was constructed based on the prognostic factors identified by the Cox hazards model. The decision curve analysis (DCA) was conducted with the training and validation set. Results The estimated 3‐, 5‐, and 10‐year DMFS were 79.4%, 71.8%, and 59.1%, respectively. The multivariate analysis revealed that age ( p = 0.033), advanced T stage ( p = 0.003), positive N stage ( p < 0.001), high‐risk pathology ( p = 0.011), and high PLR ( p = 0.001) were significantly associated with worse DMFS. The nomogram showed good calibration and discrimination in the training (AUC = 80.9) and validation set (AUC = 87.9). Furthermore, the DCA demonstrated favorable applicability, and a significant difference ( p < 0.001) was observed for the DMFS between the subgroups based on the nomogram points. Conclusion The nomogram incorporating clinicopathological features and PLR presented accurate individual prediction for DMFS of the patients with major SGCs following PORT. Further external validation of the model is warranted for clinical utility.

show abstract

Predictors of postoperative complications and survival in patients with major salivary glands malignancies: A study highlighting the influence of age

et al. 2013

View full text Add to dashboard Cite

show abstract

Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands

Abstract: Surgery and post-operative radiotherapy were effective for locoregional control. Lymphovascular invasion and perineural invasion were significant prognostic factors in patients with SDC.

Cited by 43 publications

References 21 publications

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

A nomogram involving immune‐inflammation index for predicting distant metastasis‐free survival of major salivary gland carcinoma following postoperative radiotherapy

Predictors of postoperative complications and survival in patients with major salivary glands malignancies: A study highlighting the influence of age

Contact Info

Product

Resources

About